Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kristina Fanucci, Mary Josephine Paula Pilat, Ritu Shah, Scott Anthony Boerner, Jing Li, Diane E. Durecki, Jan Drappatz, Frances A. Collichio, Vinay K. Puduvalli, Frank S. Lieberman, Javier Gonzalez, Pierre Giglio, Xun Bao, S. Percy Ivy, Ranjit Bindra, Antonio Marcilio Padula Omuro, Patricia LoRusso
Institutions: Yale Cancer Center, Wayne State University, National Institutes of Health, Yale University, University of Michigan, Michigan Medicine, UPMC Hillman Cancer Center, University of North Carolina at Chapel Hill, The Ohio State University Wexner Medical Center, University of Pittsburgh Medical Center, The Barbara Ann Karmanos Cancer Institute, National Cancer Institute, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298399